Effects of new dipeptidyl peptidase IV inhibitors on depressive behavior of mice

  • I. G. Kapitsa V.V. Zakusov Institute of Pharmacology, Moscow, Russia
  • E. A. Ivanova V.V. Zakusov Institute of Pharmacology, Moscow, Russia
  • T. A. Voronina V.V. Zakusov Institute of Pharmacology, Moscow, Russia
  • A. P. Kalinina V.V. Zakusov Institute of Pharmacology, Moscow, Russia
  • N. N. Zolotov V.V. Zakusov Institute of Pharmacology, Moscow, Russia
  • V. F. Pozdnev V.N. Orekhovich Institute of Biomedical Chemistry, Moscow, Russia
DOI: https://doi.org/10.25557/2310-0435.2018.03.39-43
Keywords: inhibitors of dipeptidyl peptidase IV (DPP-IV), depressive behavior

Abstract

A large proportion of patients with anxiety-depressive disorders exhibit signs of impaired glucose utilization and insulin resistance. Consequently, incretin-based therapies for the treatment of depressive disorders have attracted considerable attention. The goal of this study was to evaluate the effect of new dipeptidyl peptidase IV (DPP4) inhibitors on depressive behavior in outbred mice. Methods. The tail suspension test was used. The compounds were administered to outbred mice intraperitoneally either once or subchronically. Results. New DPP4 inhibitors exhibited pronounced antidepressant activity in the tail suspension test in outbred mice exceeding the activity of Sitagliptin and Vildagliptin. The results indicate that incretin-based therapies show promise for the treatment of anxiety-depressive disorders.

Published
2018-12-27
How to Cite
Kapitsa, I. G., Ivanova, E. A., Voronina, T. A., Kalinina, A. P., Zolotov, N. N., & Pozdnev, V. F. (2018). Effects of new dipeptidyl peptidase IV inhibitors on depressive behavior of mice. Patogenez (Pathogenesis), 16(3), 39-43. https://doi.org/10.25557/2310-0435.2018.03.39-43
Issue
Vol. 16 No. 3 (2018): Pathogenesis
Section
Experimental researches